	US 12,460,192 B2
	Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing
David R. Edgell, Toronto (CA); Thomas A. McMurrough, Toronto (CA); Brent E. Stead, Toronto (CA); and Odisho K. Israel, Toronto (CA)
Assigned to Specific Biologics Inc., (CA)
Filed by Specific Biologics Inc., Toronto (CA)
Filed on Apr. 21, 2025, as Appl. No. 19/184,659.
Application 19/184,659 is a continuation of application No. 17/514,585, filed on Oct. 29, 2021, granted, now 12,312,615.
Application 17/514,585 is a continuation of application No. PCT/IB2020/054229, filed on May 4, 2020.
Claims priority of provisional application 62/842,586, filed on May 3, 2019.
Claims priority of provisional application 63/019,423, filed on May 3, 2020.
Prior Publication US 2025/0297238 A1, Sep. 25, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/22 (2006.01); A61K 31/7088 (2006.01); A61K 38/46 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01)

CPC C12N 9/22 (2013.01) [A61K 31/7088 (2013.01); A61K 38/465 (2013.01); C12N 15/11 (2013.01); C12N 15/907 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)]

30 Claims

1. A method for editing DNA of a cell, comprising:

contacting the cell with a nuclease comprising a Cas9 sequence that is at least 99% identical to SEQ ID NO: 13 and comprises a glutamate at an amino acid corresponding to position 10 of SEQ ID NO: 13, wherein the nuclease edits the DNA of the cell.